<DOC>
	<DOCNO>NCT01768572</DOCNO>
	<brief_summary>Primary Objective : To assess , study , safety sarilumab tocilizumab patient rheumatoid arthritis ( RA ) inadequate responder intolerant tumor necrosis factor ( TNF ) antagonists .</brief_summary>
	<brief_title>To Evaluate The Safety SAR153191 ( REGN88 ) Tocilizumab Added Other RA Drugs Patients With RA Who Are Not Responding Intolerant Anti-TNF Therapy ( SARIL-RA-ASCERTAIN )</brief_title>
	<detailed_description>Total study duration 34 week : Screening 28 day , treatment phase 24 week , post-treatment follow-up 6 week . After completion treatment phase study , patient eligible enter long term safety study ( LTS11210 ) active treatment SAR153191 ( REGN88 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Inclusion criterion : Diagnosis RA , accord American College Rheumatology ( ACR ) /European League Rheumatism ( EULAR ) 2010 Rheumatoid Arthritis Classification Criteria ≥ 3 month disease duration . ACR Class IIII functional status , base 1991 revised criterion . Moderatetoseverely active RA . AntiTNF therapy failure , define patient inadequate clinical response define investigator , treat least 3 consecutive month , and/or intolerance least 1 TNFantagonist , result require discontinuation . TNFantagonists may include , limited , etanercept , infliximab , adalimumab , golimumab and/or certolizumab pegol . Continuous treatment one combination nonbiologic disease modify antirheumatic drug ( DMARDs ) least 12 consecutive week prior screen stable dose ( ) least 6 consecutive week prior screen : Methotrexate 10 25 mg/wk orally parenteral ( per local labeling requirement dose range differs ) Leflunomide 10 20 mg orally daily Sulfasalazine ( SSZ ) 1000 3000 mg orally daily Hydroxychloroquine ( HCQ ) 200 400 mg orally daily Exclusion criterion : Patients &lt; 18 year age . Use parenteral corticosteroid intraarticular corticosteroid within 4 week prior screen . Use oral corticosteroid dose high prednisone 10 mg equivalent per day , change dosage within 4 week prior screen . Past history , current , autoimmune inflammatory systemic localize joint disease ( ) RA . History juvenile idiopathic arthritis arthritis onset prior age 16 . Severe systemic RA , include limited vasculitis , pulmonary fibrosis , and/or Felty 's syndrome . Participation clinical research study evaluate investigational drug therapy within 5 halflives 60 day Screening Visit , whichever longer . Patients active tuberculosis latent tuberculosis infection . Prior current history interstitial lung disease . Prior treatment antiIL6 antiIL6R therapy , include limited tocilizumab sarilumab . Treatment antiTNF agent , follow : Etanercept : within 28 day prior randomization Infliximab , adalimumab , golimumab , certolizumab pegol : within 42 day prior randomization . Treatment RAdirected biologic agent non TNFα antagonist mechanism without adequate washout follow : Anakinra : within 28 day prior randomization Abatacept : within 42 day prior randomization Rituximab cell deplete agent : Within 6 month prior randomization total lymphocyte count CD 19+ lymphocyte count normalize , whichever longer . Prior treatment janus kinase ( JAK ) inhibitor ( eg , tofacitinib ) . Patients history invasive opportunistic infection . Prior current history malignancy , include lymphoproliferative disease , adequatelytreated carcinoma insitu cervix , nonmetastatic squamous cell basal cell carcinoma skin , within 5 year prior randomization ( baseline ) visit . Prior current history significant concomitant illness ( e ) , accord Investigator 's judgment , would adversely affect patient 's participation study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>